Opus Genetics, Inc. announced on November 7, 2024, the appointment of Dr. Benjamin Yerxa, Ph.D., as its new President. This appointment was approved by the independent members of the Board of Directors.
Dr. Yerxa was granted a time-based restricted stock unit award for 332,800 shares of the company's common stock as a material inducement for his employment. The award is scheduled to vest in four equal annual installments starting October 22, 2025.
Dr. Yerxa previously served as Chief Executive Officer and President of the predecessor company, Opus Genetics, Inc., prior to its acquisition in October 2024. His appointment is expected to provide leadership continuity and expertise in the company's new gene therapy focus.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.